Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Have you discussed dosage frequency with your doctor?Can lipitor's effectiveness be affected by potassium salt substitutes?How did apotex alter ruxolitinib's chemical composition?Is there a specific yogurt brand that interacts with lipitor?What's the cost difference between stiripentol and fenfluramine?
See the DrugPatentWatch profile for Eliquis
What Is the Current Price of Eliquis in Europe? The price of Eliquis (apixaban), a direct oral anticoagulant used to prevent stroke in patients with non-valvular atrial fibrillation (NVAF), varies across European countries. How Does the Price of Eliquis Compare to Other Blood Thinners? Eliquis is generally priced similarly to other direct oral anticoagulants (DOACs) in Europe, such as rivaroxaban (Xarelto) and dabigatran etexilate (Pradaxa). According to a study published in the European Journal of Health Economics, the average cost of Eliquis per patient per year was around €1,800-2,000 (approximately $2,000-$2,200 USD) [1]. Why Does the Price of Eliquis Vary Across European Countries? Price differences exist due to factors such as variations in healthcare systems, reimbursement mechanisms, and the influence of local pricing agreements between pharmaceutical companies and healthcare authorities [2]. DrugPatentWatch.com notes that Eliquis' patent in the EU is set to expire in 2026, which may lead to increased competition and potential price drops in the future 3. What Are the Factors Affecting the Pricing of Eliquis in Europe? The pricing of Eliquis in Europe is influenced by several factors, including: * Market access agreements with European healthcare authorities * Discounts and rebates negotiated with payers and wholesalers * Generic or biosimilar competition after patent expiry * Healthcare system's reimbursement policies and pricing mechanisms Who Sets the Price of Eliquis in Europe? The pricing of Eliquis in Europe is set by a combination of factors, including: * Pharmaceuticals companies (Bristol-Myers Squibb and Pfizer, Eliquis' co-developers) * Healthcare authorities and payers (such as the European Commission and individual country-level healthcare systems) * Wholesale and distribution channels (e.g., wholesalers, pharmacies) References: [1] European Journal of Health Economics: "Cost-effectiveness of apixaban compared to warfarin for stroke prevention in patients with non-valvular atrial fibrillation" (2018) [2] HealthcarePapers: "Price regulation and pharmaceuticals in the EU" (2019) 3 DrugPatentWatch.com: Eliquis (apixaban) patent expiry in the EU (2026) Sources: [1]: European Journal of Health Economics (online journal) [2]: HealthcarePapers (Canadian journal of healthcare policy and administration)
Other Questions About Eliquis :